Characterization of zolbetuximab in pancreatic cancer models

DOI: 10.1080/2162402X.2018.1523096

Keywords: Claudin 18.2, zolbetuximab, IMAB362, monoclonal antibody, targeted therapy, pancreatic cancer, antibody-dependent cellular cytotoxicity, ADCC, complement-dependent cytotoxicity, immunotherapy

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text